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Abstract
Genotype imputation has become standard practice in modern genetic studies. As sequencing-based reference panels
continue to grow, increasingly more markers are being well or better imputed but at the same time, even more markers
with relatively low minor allele frequency are being imputed with low imputation quality. Here, we propose new methods
that incorporate imputation uncertainty for downstream association analysis, with improved power and/or computational
efficiency. We consider two scenarios: I) when posterior probabilities of all potential genotypes are estimated; and II) when
only the one-dimensional summary statistic, imputed dosage, is available. For scenario I, we have developed an
expectation-maximization likelihood-ratio test for association based on posterior probabilities. When only imputed dosages
are available (scenario II), we first sample the genotype probabilities from its posterior distribution given the dosages, and
then apply the EM-LRT on the sampled probabilities. Our simulations show that type I error of the proposed EM-LRT
methods under both scenarios are protected. Compared with existing methods, EM-LRT-Prob (for scenario I) offers optimal
statistical power across a wide spectrum of MAF and imputation quality. EM-LRT-Dose (for scenario II) achieves a similar
level of statistical power as EM-LRT-Prob and, outperforms the standard Dosage method, especially for markers with
relatively low MAF or imputation quality. Applications to two real data sets, the Cebu Longitudinal Health and Nutrition
Survey study and the Women’s Health Initiative Study, provide further support to the validity and efficiency of our proposed
methods.
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Introduction
Genotype imputation has become standard practice in modern
genetic studies [1] [2][3] [4]. For each untyped variant imputed,
standard imputation methods estimate posterior probabilities of all
possible genotypes. For example, when the untyped variant is bi-
allelic with alleles A and B, we obtain posterior probabilities for A/
A, A/B, and B/B with the constraint of summation being one.
Such probability information can be further summarized into
degenerate one-dimensional summary statistics including the
mode (the best guess genotype, or the genotype with the highest
posterior probability), or the mean (the imputed dosage).
Since association analysis with phenotypes of interest rather
than genotype imputation per se is usually of the ultimate interest,
development and evaluation of post-imputation association
strategies have therefore attracted considerable attention from
the research community [5][6][7][8][9][10][11][12][13]. Among
them, imputation dosage based methods provide an attractive
compromise between modeling complexity, computational effi-
ciency and statistical power, have been shown analytically to be
optimal among methods based on one-dimensional summary
statistics [11], and thus have been most commonly adopted in
recent imputation-aided genome-wide association studies (GWAS)
and meta-analyses [14][15][16][17]. On the other hand, explicitly
modeling the probabilities of all possible genotypes using the
mixture of regression models (abbreviated Mixture hereafter and
detailed below) has the best performance in terms of statistical
efficiency, particularly with low imputation quality, but at the cost
of increased computational complexity [13].
Limited evaluations of existing methods (including methods that
explicitly model posterior probabilities) on variants with low
imputation quality suggest much reduced power compared with
accurately imputed variants, for instance, as demonstrated in
Figure 2 and 3 [13] and Figure 2 [11]. Analysis of variants with
low imputation quality is not surprisingly a challenging problem
due to the low correlation between imputed and true genotypes. It
is nevertheless an increasingly important problem because as
sequencing-based reference panels continue to grow [18][19], we
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data collection and analysis, decision to publish, or preparation of the manuscript.
listing of WHI investigators can be found at: (https://www.whi.org/researchers/SitePages/WHI%20Investigators.aspx) The funders had no role in study design,
have increasingly more well imputed markers but also even more
markers with relatively low imputation quality, particularly at
markers with lower allele frequencies [20][21][22][23][24]. It is
thus highly warranted to seek alternative and potentially more
efficient methods to model imputation uncertainty for these
markers. In this work, we develop expectation-maximization
likelihood-ratio tests (EM-LRT) that can accommodate either
posterior genotype probabilities, when available (EM-LRT-Prob),
or imputed dosages (EM-LRT-Dose). Simulations and real data
application demonstrate the validity of the proposed methods and
suggest them as a computationally more efficient alternative to the
best existing method (Mixture) for association analysis of variants
with low MAF or imputation quality.
Methods
We will first briefly review the Mixture method [13] given it is
the state-of-the-art method that models the posterior probabilities.
We will then proceed to introduce our methods by first
introducing a hierarchical modeling framework to simulate
genotype (including both the truth and imputed) and phenotype
data of interest, explicitly taking imputation quality (as measured
by R2, squared Pearson correlation between true and imputed
genotypes) into account. This framework allows us to simulate data
conditional on any desired R2, making it straightforward to
evaluate performance at any desired level of imputation quality.
We then describe our EM-LRT in two scenarios, namely when
posterior probabilities are available (Scenario I) and when only
imputed dosages are available (Scenario II).
Brief Review of the Mixture Method
The following mixture of regression model is fit for trait Yi and




fij :gj b0,b1,c,eið Þ
where gj b0,b1,c,eið Þ~b0zj:b1zcZizei, Zi is the covariate
vector, ei*N 0,s2
 
, and i = 1, 2, …, N with N being the sample
size. To estimate the parameters b0,b1,cð Þ, the log-likelihood
function is maximized using the Nelder-Mead Simplex Method
[25], implemented in R package optim.
A Hierarchical Modeling Framework to Simulate Data
We adopt a hierarchical model that generates posterior
probabilities, imputed dosages, and true genotypes using marker-
specific information including minor allele frequency (MAF) and
imputation quality measure (R2), as well as a quantitative trait with
which we test for genetic association. The model has three stages:
the first stage generates genotype probabilities based on marker-
specific information (genotype probability stage); the second stage
employs a multinomial distribution with probabilities from the first
stage to generate allele counts (allele count stage); and the final
stage fits a linear regression model to generate quantitative trait
values (trait stage).
Genotype Probability Stage. For a specific marker with
MAF q and imputation quality R2, the genotype probability vector
Fi~ fi0,fi1,fi2ð Þ for the i-th sample is drawn from a Dirichlet
distribution with parameters a~ a0,a1,a2ð Þ, where fij is the
Figure 1. MAF Threshold: Rejection Sampling (Black) vs. Dosage Approximation (Grey). The MSE (Y-axis) between sampled genotype
probability f̂1 and true f1 using rejection sampling (black) and dosage approximation (grey) is compared across a spectrum of R
2.
doi:10.1371/journal.pone.0110679.g001
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probability of having j copies of the minor allele for the i-th sample
and
P2
j~0 fij~1. The parameters in the Dirichlet distribution are:
a0~ 1{qð Þ2=c , a1~2q 1{qð Þ=c , a2~q2=c with c~R2=
1{R2
 
. We provide details to justify this choice the parameters
a~ a0,a1,a2ð Þ in Appendix S1. Here we give some brief
explanations. First, this distribution gives reasonable expected
values for Fi~ fi0,fi1,fi2ð Þ such that E fi0ð Þ~ 1{qð Þ2,
E fi1ð Þ~2q 1{qð Þ, and E fi2ð Þ~q2, which are the expected
probabilities of having 0, 1, or 2 copies of minor alleles assuming
Hardy-Weinberg Equilibrium. Next, when R2 approaches to 1,
Fi~ fi0,fi1,fi2ð Þ approaches to a distribution that takes three
possible values, (1,0,0), (0,1,0), and (0,0,1) (i.e., the probability of
having a particular genotype is either 0 or 1), which is the expected
situation when there is no imputation ambiguity. Given the
genotype probability vector, the imputed dosage is Di~fi1z2fi2.
Allele Count Stage. The allele count vector
Xi~ xi0,xi1,xi2ð Þ for the i-th sample is drawn from a multino-
mial distribution with genotype probabilities specified in the
previous stage, where xij~1 if the i-th sample has j copies of the
minor allele; and 0 otherwise, with the constraint ofP2
j~0 xij~1. Additionally, the genotype Gi for the i-th sample
is generated using this allele count vector, specifically
Gi~xi1z2xi2. Our simulation framework, taking imputation
Table 1. Rejection Sampling vs. Dosage Approximation for fi1 Estimation.
Rejection Sampling Dosage Approximation
R2 MAF Cutoff MSE Runtime (Sec.) MSE Runtime (Sec.)
0.95 20% 1.01E-02 5.82 1.42E-02 7.60E-04
0.75 30% 4.49E-02 3.04 6.39E-02 6.80E-04
0.50 30% 5.98E-02 2.3 6.29E-02 7.14E-04
0.30 30% 5.71E-02 2.42 6.11E-02 8.10E-04
0.25 30% 5.32E-02 2.61 6.06E-02 8.36E-04
0.20 25% 3.82E-02 2.41 3.93E-02 7.56E-04
0.10 20% 1.69E-02 2.35 1.99E-02 7.04E-04
MAF: Minor allele frequency.
MSE: Mean square error.
doi:10.1371/journal.pone.0110679.t001
Figure 2. Spearman Correlation with Gold Standard P-values. The Spearman correlation (Y-axis) between gold standard p-values and p-
values from different methods is displayed across a spectrum of MAF and R2.
doi:10.1371/journal.pone.0110679.g002
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quality R2 into account using c above, renders corr2 Gi,Dið Þ~R2
[proof in Appendix S1; Figure S2 and S3].
Trait Stage. In the final stage, a linear regression model is





and i = 1, 2, …, N.
Expectation-Maximization Likelihood-Ratio Tests
Our primary goal is to test for marker-trait association when
marker genotypes G are not directly observed but rather
imputed. We propose the following expectation-maximization
likelihood-ratio tests (EM-LRT). We consider two common
scenarios after genotype imputation: 1) when posterior
probabilities of genotypes are available and 2) when only
dosages are available.
Scenario I: When Posterior Probabilities Are Available
[EM-LRT-Prob]. Under this scenario, the true genotype Gi is
missing but genotype probability vector Fi~ fi0,fi1,fi2ð Þ is estimat-
ed, i = 1, 2, …, N with N being the sample size. Given the
observations yi,Gi,zi,fið Þ where fi is the observed value for Fi, the
complete data likelihood is.
Table 2. Type I Error at Significance Level = 5E-02.
R2 MAF Dosage EM-LRT-Dose EM-LRT-Prob Mixture Truth
0.3 0.2 4.99E-02 5.01E-02 5.01E-02 5.01E-02 4.99E-02
0.1 5.01E-02 5.02E-02 5.03E-02 5.03E-02 4.99E-02
0.05 4.99E-02 5.01E-02 5.01E-02 5.01E-02 4.99E-02
0.025 5.01E-02 5.03E-02 5.03E-02 5.03E-02 5.01E-02
0.01 4.98E-02 4.96E-02 4.96E-02 4.96E-02 4.99E-02
0.2 0.2 5.00E-02 5.02E-02 5.03E-02 5.03E-02 5.00E-02
0.1 4.99E-02 5.02E-02 5.03E-02 5.03E-02 5.00E-02
0.05 5.00E-02 5.03E-02 5.03E-02 5.03E-02 5.01E-02
0.025 4.99E-02 5.03E-02 5.03E-02 5.03E-02 5.01E-02
0.01 5.00E-02 5.02E-02 5.01E-02 5.01E-02 4.99E-02
0.1 0.2 5.00E-02 5.08E-02 5.05E-02 5.05E-02 5.01E-02
0.1 5.00E-02 5.06E-02 5.08E-02 5.08E-02 5.00E-02
0.05 5.01E-02 5.11E-02 5.13E-02 5.13E-02 5.01E-02
0.025 5.01E-02 5.15E-02 5.14E-02 5.14E-02 5.01E-02
0.01 5.00E-02 5.09E-02 5.07E-02 5.07E-02 4.98E-02
doi:10.1371/journal.pone.0110679.t002
Table 3. Type I Error at Significance Level = 5E-05.
R2 MAF Dosage EM-LRT-Dose EM-LRT-Prob Mixture Truth
0.3 0.2 4.85E-05 5.00E-05 4.94E-05 4.94E-05 5.24E-05
0.1 5.09E-05 4.98E-05 5.23E-05 5.23E-05 5.43E-05
0.05 4.71E-05 5.03E-05 5.07E-05 5.07E-05 5.41E-05
0.025 4.95E-05 4.92E-05 4.80E-05 4.80E-05 4.97E-05
0.01 5.35E-05 4.79E-05 4.69E-05 4.69E-05 4.97E-05
0.2 0.2 4.58E-05 4.57E-05 4.58E-05 4.58E-05 5.00E-05
0.1 4.67E-05 4.71E-05 4.84E-05 4.84E-05 5.30E-05
0.05 5.08E-05 5.09E-05 5.05E-05 5.05E-05 5.14E-05
0.025 5.23E-05 5.02E-05 5.09E-05 5.09E-05 5.06E-05
0.01 4.78E-05 4.41E-05 4.26E-05 4.26E-05 4.92E-05
0.1 0.2 4.93E-05 5.53E-05 5.19E-05 5.19E-05 5.02E-05
0.1 5.08E-05 5.27E-05 5.24E-05 5.24E-05 5.35E-05
0.05 5.05E-05 5.09E-05 5.23E-05 5.22E-05 4.85E-05
0.025 4.98E-05 5.15E-05 5.04E-05 5.04E-05 4.93E-05
0.01 5.02E-05 5.05E-05 4.95E-05 4.95E-05 5.27E-05
doi:10.1371/journal.pone.0110679.t003
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Figure 3. Power Comparison. The statistical power (Y-axis) of the different methods is shown across a spectrum of R2 and MAF.
doi:10.1371/journal.pone.0110679.g003
Figure 4. Q–Q Plot for Null Variants with Low Imputation Quality in the CLHNS Study. The observed (Y-axis) vs. expected (X-axis) –log10[p-
values] are shown for 1,135 SNPs in the CLHNS data set. These SNPs are considered to be under the null hypothesis (true p-value .561026), and all
have low imputation quality (R2,0.3).
doi:10.1371/journal.pone.0110679.g004
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L b,s,cDy,G,z,fð Þ
~PNi~1 f yi DGi,zi,fið Þ:P Gi Dzi,fið Þ
~PNi~1 f yi DGi,zið Þ:P Gi Dfið Þ!PNi~1 f yi DGi,zið Þ
where the second equality holds because trait yi is independent of
genotype probability vector fi conditional on true genotype Gi and
true genotype is independent of covariates zi conditional on
genotype probability vector. Therefore, with Gaussian distribu-




{logs{ yi{ b0zb1Gizczið Þ½ 2
.
2s2
In this complete data log-likelihood, terms involving true
genotype Gi, namely Gi and Gi
2, are not observed and will be
replaced in the E-step by their conditional expectations given the
observed data. Their conditional expectations are.




Gi:P Gi Dyi,fi,zið Þ~C{1:
X2
Gi~0















f yi DGi,zið Þ:P Gi Dfið Þ, and







In the M-step, the maximum likelihood (ML) estimates of the
parameter h~ b0,b1,c,sð Þ are obtained as follows:
b̂0,b̂1,ĉ
 
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We repeat the E-step and M-step until convergence (dv10{6).
To speed up the EM algorithm, we suggest using the naı̈ve
parameter estimates as starting values, that is, the parameter
estimates derived by fitting a simple linear regression on trait Y using
dosage D and covariates Z (a.k.a Dosage or standard method). Our
EM-LRT-Prob approach shares some similarity with the seminar
work by Lander and Botstein [26] for interval mapping, in which
the authors also used mixture model framework, treating genotypes
at quantitative trait loci as missing data.
Table 4. Associated Variants with R2#0.3 in the CLHNS Study.
P-values
Coordinate* R2 Dosage EM-LRT-Dose EM-LRT-Prob Mixture Truth#
chr16:82646152 0.251 2.13E-11 1.45E-11{ 4.68E-11 4.68E-11 6.77E-20
chr16:82650717 0.282 2.88E-11 1.83E-11{ 5.87E-11 5.87E-11 1.35E-21
chr16:82663288 0.268 2.67E-10{ 7.78E-10 6.46E-10 6.46E-10 2.16E-25
chr16:82670249 0.270 2.04E-08 1.45E-08{ 1.59E-08 1.61E-08 1.72E-12
chr16:82670539 0.249 9.26E-09 1.27E-08 4.79E-09{ 4.83E-09 1.25E-12
chr16:82670636 0.230 1.22E-08 2.01E-08 7.32E-09{ 7.33E-09 1.78E-12
*: Coordinates are in genome build 37.
Bold with {: The most significant p-value among the four methods.
Bold without {: The second most significant p-values among the four methods.
#: Truth was established by regressing phenotype on true genotypes.
doi:10.1371/journal.pone.0110679.t004
Table 5. Associated Variants with MAF ,5% in the WHI Study.
P-value
SNP Trait Meta p-value Dosage EM-LRT-Dose
snp.684276 hematocrit 5.70E-11 5.85E-11* 8.94E-11
snp.177048 log(WBC) 3.00E-13 3.95E-08 2.73E-08*
snp.177015 log(WBC) 4.30E-13 6.11E-08 4.72E-08*
snp.41127 platelet 1.50E-11 2.52E-08 3.71E-09*
*: The most significant p-value among the two methods.
doi:10.1371/journal.pone.0110679.t005
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Scenario II: When Only Dosages Are Available [EM-LRT-
Dose]. We propose a framework that first uses the conditional (on
dosages) distribution to sample genotype probabilities given the
imputed dosages, and then apply the EM algorithm detailed above
in Scenario I.
First, we derive the probability density function for fi1, the
probability of having one copy of the minor allele conditioning on
imputed dosage.
Figure 5. Computing Time: Mixture Method vs EM-LRT-Prob. The computing time of the Mixture method and our proposed EM-LRT-Prob
method is displayed across a range of sample sizes. For each sample size, computing time is averaged across 2,000 simulated datasets.
doi:10.1371/journal.pone.0110679.g005
Table 6. One-sample T-test for Type I Error.
P-values
MAF Method R2 = 0.05 R2 = 0.1 R2 = 0.3 R2 = 0.5
0.025 Dosage 6.75E-01 2.72E-01 4.97E-01 7.33E-01
0.05 2.03E-01 6.38E-01 9.21E-01 1.88E-01
0.1 9.62E-01 8.75E-01 2.01E-01 6.78E-01
0.025 EM-LRT-Dose 8.96E-183* 3.00E-65* 2.00E-01 9.05E-01
0.05 6.15E-216* 5.11E-35* 3.89E-01 7.33E-03
0.1 1.40E-69* 9.73E-12* 4.73E-03 4.17E-02
0.025 EM-LRT-Prob 2.34E-111* 2.51E-55* 2.49E-01 8.69E-01
0.05 1.54E-174* 3.38E-40* 2.50E-01 4.81E-03
0.1 4.24E-134* 1.04E-24* 5.01E-04 2.91E-02
0.025 Mixture 5.45E-111* 3.72E-55* 2.52E-01 8.70E-01
0.05 2.94E-174* 4.79E-40* 2.55E-01 4.98E-03
0.1 7.60E-134* 1.22E-24* 5.30E-04 2.95E-02
*: P-value ,5E-4.
doi:10.1371/journal.pone.0110679.t006
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f fi1~pD ið Þ~
C’
B að Þ
: 1{0:5 Dizpð Þ½ a0{1pa1{1 0:5 Di{pð Þ½ a2{1
where C9 is the normalizing constant, p[ 0,min 2{Di,1,Dið Þ½ , and
B(.) is the beta function [Appendix S2]. Second, we select the envelope
function g pð Þ~ max
p
f fi1~pD ið Þ such that f pð Þƒg pð Þ for all p.
Third, we perform the following steps to sample fi1: 1) generate
p*U 0,min 2{Di,1,Dið Þð Þ; 2) generate U*U 0,1ð Þ; 3) accept p if




The drawback of the above rejection sampling approach is that
it can be computationally rather expensive especially when the
envelope function is large. Fortunately, we can use an approxi-
mation approach when MAF is not high. For example, when MAF
is low enough, the probability of having two copies of the minor
allele is close to zero. In that case, we adopt an approximation
approach (referred hereafter as dosage approximation approach)
by setting the probability of having one copy of the minor allele to
dosage when MAF is below certain threshold depending on the
imputation quality [details are shown below in subsection
Numerical Simulation: MAF Threshold].
Hypothesis Testing
To assess whether a variant is associated with phenotypic trait of
interest Y, we perform the following hypothesis testing H0 : b1~0
vs. H1 : b1=0. Note that the same b1 is assumed across all three
possible genotypes. We propose to use the likelihood-ratio test for
this purpose. Specifically, hypothesis testing is performed as
follows: 1) use the EM algorithm described previously to find the
ML estimates ĥ for h~ b0,b1,c,sð Þ, and then compute the log-
likelihood l ĥ
 
; 2) find the ML estimates ĥ under H0; and 3)





. The LRT will reject the H0 if
LRSwx2a, where x
2
a is the 1{að Þ100
th percentile of the x2a-
distribution with degree of freedom (d.f.) = 1.
Numerical Simulation
MAF Threshold. To achieve optimal balance between
performance and computational efficiency, we use extensive
simulations to find the MAF threshold between the choice of
rejection sampling and dosage approximation. Given R2, we
calculate two sets of mean squared error (MSE) between sampled
genotype probability f̂i1 and truth fi1 using rejection sampling and
dosage approximation, respectively.
Type I Error Evaluation. We assess the validity of EM-
LRT-Dose, Dosage, EM-LRT-Prob, Mixture and gold-standard
(based on true genotypes) under various combinations of R2 and
MAF. Specifically, we simulate data sets each with 2,000 samples
using pre-specified marker-specific information R2 and MAF,
which allows us to generate genotype probabilities, dosages, and
true genotypes. Next, we simulate the trait values Yi according to
the linear model for sample i with a set of pre-specified
parameters, where i = 1, …, 2,000. For simplicity, we set
b0,b1,c,sð Þ~ 1,0,1,1ð Þ.
We repeat the simulation ten million times. For each simulated
data set, we perform association testing based on the true
genotypes (truth), as well as based on imputed data using the
standard Dosage method, Mixture method, and our proposed
EM-LRT-Prob and EM-LRT-Dose methods. The empirical type
I error of each method is calculated as the proportion of observed
p-values that fall below the specified significance level. In addition,
we calculate the Spearman correlation between the observed and
gold-standard (true genotype based) p-values.
Statistical Power Assessment. To evaluate the statistical
power of different methods, we again simulate data sets each with
2,000 samples using a combination of marker-specific information
R2 and MAF, and parameters b0,b1,c,sð Þ~ 1,b1,1,1ð Þ where
b1[ 0,1:5½ . We again repeat the simulations one million times.
Similarly, for each simulated data set, we performed the same set
of tests. The power of each method is calculated as the proportion




We used simulations to determine the MAF threshold specific to
each R2 such that the rejection sampling is advantageous
(quantified by lower MSE in estimating fi1, the probability of
having one copy of the minor allele) over dosage approximation
when exceeding the MAF threshold (Figure 1 and Table 1). We
observed the two sampling methods have similar performance
(measured by MSE) when MAF is not high (below 20%–30%
depending on R2). In such cases, we chose the simple dosage
approximation method due to computational efficiency (Runtimes
for rejection sampling and dosage approximation based on 2,000
samples are also shown). We also observed inferior performance
(larger MSE) of both methods for low MAFs with intermediate R2
values. Both can be explained by a combination of the imputation
quality and the variation in fi1 as a function of both imputation
quality R2 and MAF q. Specifically, we have Var(fi1) = R
2 62q(1–
q) 6 (1–2q(1– q)), which increases with MAF q as well as with R2.
Low imputation quality R2 coupled with low MAF leads to
relatively little variation in fi1, rendering both sampling methods
capable of estimating it relatively accurately. On the other hand,
high imputation quality implies dosages close to true genotype
values 0, 1, and 2, as well as fi1 close to 0 or 1, thus allowing
accurate inference of fi1 despite the larger variation in the values of
fi1 across individuals. In the intermediate R
2 range, variation in fi1
coupled with imputation uncertainty makes inference challenging
for both approaches.
Empirical Type I Error Simulation Results
As shown in Table 2 (at significance level 5E-02) and Table 3
(at significance level 5E-05), all the methods have proper control of
type I error across in the range of R2 and MAF examined: 0.1#
R2#0.3 and 1% # MAF #20%. Next, as shown in Figure 2,
Spearman correlation with true p-values increases for every
method when R2 increases. The overall correlation is low in the
range of MAF and R2 examined. This low correlation is expected
given the high level of imputation uncertainty and consistent with
previous results [13], confirming that association inference is
challenging with low frequency variants, or with variants imputed
with a high level of uncertainty. Although the absolute perfor-
mance of all methods is not particularly impressive, we observe
that EM-LRT methods always show slightly higher Spearman
correlation than Dosage method especially when MAF is low,
suggesting that the EM-LRT p-values better approach gold-
standard p-values. When R2 and MAF are high, all methods
perform similarly (results not shown), consistent with results shown
in literature [11] [13].
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Empirical Power Simulations Results
When R2 and MAF are high, all methods have similar
performance. In this work, we focus on scenarios where 0.1#
R2#0.3 and 1% # MAF #20%. As shown in Figure 3, EM-LRT-
Prob and Mixture methods are consistently the most powerful
methods among all methods evaluated. However, these methods
are not applicable in scenario II when only imputed dosages are
available. It is thus valuable to notice that EM-LRT-Dose method
approaches the statistical efficiency of EM-LRT-Prob, outper-
formng the standard Dosage method especially when R2 or MAF
is low. For example, when R2 = 0.1 and MAF = 0.05, the power
for EM-LRT-Prob, Mixture, EM-LRT-Dose and Dosage are
84.5%, 84.5%, 82.1%, and 61.4% under b1 = 1.
Application to CLHNS Data Set
We applied the proposed EM-LRT methods as well as other
existing methods to the Cebu Longitudinal Health and Nutrition
Survey (CLHNS) study of 1,800 unrelated Filipino women. We
performed association analysis across chromosome 16, where we
have previously identified the variants near CDH13 gene
associated with plasma adiponectin level [27].
We conducted association testing with standardized adiponectin
level measured in 2005 on a log scale as the quantitative trait and
adjusted for age and BMI also measured in 2005. Additionally, we
excluded subjects from the analysis if they met one or more of the
following criteria: 1) subjects with adiponectin level missing or
outside of the range mean +/24 standard deviations (n = 19); 2)
subjects carrying the R221S variant (n = 53) [28]; and 3) subjects
with missing age or BMI covariate information (n = 20). In total,
1,717 subjects were tested for association with adiponectin level.
These 1,717 subjects were genotyped on the Affymetrix
Genomewide Human SNP Array 5.0 GWAS chip [29] and also
on the Illumina HumanExome Beadchip. Specifically, we first
established the truth by employing PLINK [30] to perform
association on the true genotypes separately, finding 10 true
positives (p-value ,561026) on Affymetrix 5.0 and 5 on exome
chip (with 2 overlapping). Next, to mimic a setting of low
imputation quality, we masked all neighboring GWAS SNPs
within 2 kb of the 13 true positives before genotype imputation (22
SNPs were masked). Finally, we performed imputation using the
MaCH imputation software [31] using the ASN panel from the
Phase I 1000 Genomes Project (March 2012 release, version 3) as
reference. To evaluate the performance of the proposed methods
along with other alternatives, we used markers overlapping
between the ASN reference panel and the exome chip, but not
on the Affymetrix 5.0, at which we have both imputed genotypes
and true genotypes (from exome chip genotyping). We then
conducted association testing on the imputed genotypes (dosages
or probabilities) using our proposed EM-LRT methods, Dosage,
and Mixture method.
Figure 4 shows the Q–Q plot for the 1,135 SNPs on
chromosome 16 with R2 # 0.3 and true p-value .561026. Q–
Q plots are used to assess the number and magnitude of observed
associations between tested SNPs and the trait under study, by
comparing the observed –log10 p-values to what is expected under
the null hypothesis of no association. Early departure from the
identity line suggests either that there is uncontrolled confouding
leading to false positives (for example, due to population
stratification) or that a considerable proportion of SNPs are
associated with the trait of interest (and thus not under the null
distribution). Focusing on variants with p-values .561026 based
on experimental genotypes allowed us to examine the type I error
empirically. Overall, this Q–Q plot suggests that all methods have
proper control of type I error with all points falling within the 95%
confidence bands with the exeption of one variant. The single
potential false positive, rs8045889 with a true p-value = 0.0148;
R2 = 0.0736; and MAF = 0.4271, was identified by Dosage, EM-
LRT-Prob, and Mixture (EM-LRT-Dose has a borderline p-value
of 0.0002). In addition, we observe overall deflation in the test
statistics (observed larger p-values) of all methods when compared
with truth. The median (mean) p-values are 0.6407, 0.5614,
0.5568 and 0.5568 (0.6075, 0.5552, 0.5512, and 0.5543) for
Dosage, EM-LRT-Dose, EM-LRT-Prob and Mixture respective-
ly, compared with the true median (mean) of 0.5008 (0.5009). The
tendency towards large p-values is expected and driven by the loss
of information due to imputation uncertainty.
While establishing the validity is crucial, we are more interested
in the power to identify genuine associations. Table 4 tabulates p-
values from all four methods together with the truth for variants
with R2,0.3 and true p-value ,561028. Although all variants
reach the genome-wide significance threshold regardless of the
method, we observed that EM-LRT-Dose or EM-LRT-Prob
generated more significant p-values (and better approached truth
in all cases) than the alternatives for five out of the six variants
interrogated, suggesting power enhancement using our methods.
Application to the Women’s Initiative Study of Blood Cell
Traits
We have previously identified several variants associated with
blood cell traits using whole exome sequencing in 761 African
Americans coupled with imputation in .13,000 African Ameri-
cans with GWAS data from genome-wide Affymetrix 6.0
genotyping [14]. The samples are drawn from several cohorts
including WHI, ARIC, CARDIA and JHS. Association analyses
were performed separately for WHI and CARe cohorts (ARIC,
CARDIA and JHS) and subsequently meta-analyzed across the
two. Due to the ascertainment of variants through whole exome
sequencing, 56% of our analyzed variants had MAF ,5%.
Here, we use meta-analysis results from our previous study as a
gold standard to define true positives and investigate the p-values
in the WHI cohort using our EM-LRT-Dose and standard Dosage
method, which had been adopted by the original study. We did
not keep a copy of the posterior probabilities because of the large
number of samples imputed and because standard analyses do not
involve the posterior probabilities. Therefore, this is a real data
example of scenario II. Table 5 presents all variants with MAF ,
5% reported to reach genome-wide significant threshold in the
original study, comparing p-values from our EM-LRT-Dose and
the standard Dosage method. We notice that EM-LRT-Dose
generated slightly more significant p-values at the associated
variants in three out of the four tests performed. In one case
(snp.177015 with white blood cell count [WBC]), the p-value from
EM-LRT-Dose (p-value = 4.7261028) reached the conventionally
employed genome-wide significance threshold of 561028 while
that from Dosage was marginally genome-wide insignificant (p-
value = 6.1161028).
Discussion
It is crucial to take imputation uncertainty into consideration
when performing association testing. Existing methods have
focused on common variants, which have been the focus of the
past wave of GWAS using HapMap-based imputation. With the
deluge of next generation sequencing data being generated,
increasingly denser reference panels are allowing imputation of a
much larger number of variants, including an increasing number
of relatively rare or poorly imputed variants. It is thus highly
warranted to re-visit potential strategies for post-imputation
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association analysis and to seek more powerful or efficient
statistical methods.
In this work, we have proposed EM-LRT methods explicitly
incorporating marker level imputation quality statistic into
association tests. We considered two scenarios: when posterior
probabilities of all potential genotypes are available and when only
dosages are available. We evaluated the performance of the
proposed methods along with existing alternatives using simulation
studies and by application to real data sets.
In scenario I, our proposed EM-LRT-Prob demonstrated
nearly identical performance as the Mixture model, which has
been shown to be the best post-imputation association method
particularly when imputation uncertainty is high [13]. While our
EM-LRT-Prob effectively also fits a mixture model (therefore in
terms of the underlying statistical model essentially the same as the
Mixture method [13]), we have proposed and implemented a
much more computationally efficient algorithm to fit the model.
Mixture method used R function optim() to find ML estimates.
Technically, the optim() function uses numerical differentiation to
obtain ML estimates based on the score function and Hessian
matrix, which is considerably slower than our proposed EM
algorithm. To quantify the computational efficiency, we conduct-
ed association testing on a CLHNS data set of 1,717 subjects and
13,801 SNPs, using EM-LRT-Prob and Mixture methods with the
same starting values (the Mixture method tends to run even slower
without using the suggested starting values). We observed that the
association tests required 279 seconds computing time and 0.91
GB RAM for EM-LRT-Prob and 1,505 seconds computing time
and 1.23 GB RAM for the Mixture method on a 2.93 GHz Intel
Xeon Processor X5670. Computing time scales linearly with
sample size for both EM-LRT-Prob and the Mixture method
(Figure 5).
In scenario II, the Dosage method has been shown analytically
as the optimal one dimensional summary statistic for association
testing in a typical linear model [11]. In this work, we extended the
utility of this optimal one-dimensional measure by employing it
together with the imputation quality measure R2 first to sample
posterior probabilities (in an attempt to rescue as much full
information as possible) and then to conduct association testing on
the sampled probabilities using our proposed EM-LRT method.
Our simulations suggest an advantage of the proposed methods
over the standard Dosage method when imputation quality is
relatively low, where imputation quality is measured by R2, the
squared Pearson correlation between the imputed dosages and the
unknown true genotypes. Since the calculation of R2 requires true
genotypes, it is not available in practice and imputation software
provides an estimate based on the observed dispersion in imputed
genotypes over its expected value. Such an estimate (Rsq in
MaCH [31], MaCH-Admix [32], minimac [33]; R2 for BEAGLE
[1] and INFO for IMPUTE/IMPUTE2 [34][35]) has been widely
used for the assessment of imputation quality and for post-
imputation quality control. However, as shown in Figure S1 (based
on the CLHNS data), MaCH Rsq is not a perfect measure of R2.
For example, it has been reported earlier to have the tendency of
underestimating true quality for common variants [36][22]. We
also observed the tendency of over-estimation towards the lower
end of the MaCH Rsq. Therefore, we still recommend post-
imputation quality filtering before application of our methods. We
suggest application to variants with estimated R2.0.1, which is
less stringent than what is typically recommended [20][22], but
above which imputation quality is typically under- rather than
over- estimated. To further examine the effectiveness of the
filtering threshold, we quantified type I error via simulations for
varying R2 (four values examined: 0.05, 0.1, 0.3, 0.5) in
combination with varying MAF (three values examined: 2.5%,
5% or 10%). Specifically, for each R2 and MAF combination, we
simulated A (A = 2500) (exchangeable) groups of data sets under
the null hypothesis. For each group, we simulated B (B = 2000)
data sets (again, under the null hypothesis) and calculated the p-
values by applying all methods to each of the B = 2000 simulated
datasets. We then calculated the group-specific type I error as the
proportion of B = 2000 p-values (in that group) below the
significance threshold of 0.05. We therefore obtained A = 2500
type I error estimates. Finally, we conducted the following one-
sample t-test on these 2500 type I error estimates H0: type I error
#0.05 vs. H1: type I error .0.05. Significant results from the t-test
indicate inflated type I error. Results are shown in Table 6. As we
can see the results suggest that the mixture model based methods
(EM-LRT-Dose, EM-LRT-Prob, and Mixture) have inflated type
I error when R2#0.1, which is likely caused by the tendency of the
mixture model over-fitting the data based on additional d.f.
compared to the null model.
In summary, we have proposed likelihood-ratio tests based on
expectation maximization algorithms for post-imputation associ-
ation testing. Simulation and real data analyses show our methods
have protected type I error. In addition, simulation and real data
results suggest slightly enhanced statistical power of our EM-LRT
methods over a standard Dosage test, which has been shown to be
the optimal one dimensional statistic for post-imputation associ-
ation testing; and computationally more efficient (average more
than fivefold reduction in computing time) than the Mixture
method, which has been shown to be the most powerful at
increased computational costs for variants imputed with high level
of uncertainty. We anticipate our methods will replace the Mixture
method for the analysis of low frequency variants or those imputed
with high uncertainty. We envision our methods being applied on
a larger scale for GWAS studies with imputation from sequencing
based reference panels, including in the public domain, the 1000
Genomes Project [37][18], the UK10K Project [38], and the
reference haplotypes assembled by the International Haplotype
Consortium [39], as well as study specific reference panels [22]
[40][14][41][20][42][43]. Our methods are implemented in
software package EM-LRT, freely available at http://www.unc.
edu/,yunmli/emlrt.html.
Supplementary Data
Supplemental Data, which include two appendixes and three
figures, can be found with the article.
Supporting Information
Figure S1 Estimated versus True Imputation Quality (Rsq vs.
R2). The MaCH estimated imputation quality Rsq (Y-axis) is
plotted against the true imputation quality R2 (X-axis), which were
calculated between genotype data from exome chip array and
imputed genotype data (dosages). The red 45-degree line
represents perfect estimation. A smooth density scatter plot is
employed such that darker color corresponds to larger density and
individual dots represent outliers.
(TIF)
Figure S2 Variance of Dosages vs. Variance of Genotypes. The
variance of dosages (Y-axis) is plotted against the variance of
genotypes (X-axis) computed using imputed dosages and genotype
data from exome chip array in the CLHNS study. The red 45-
degree line represents perfect correlation.
(TIF)
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Figure S3 Boxplot of Observed R2. The observed R2 (Y-axis) is
shown across a spectrum of true R2 (X-axis) and MAF.
(TIF)
Appendix S1 Simulation of data with desired imputation quality
R2.
(PDF)
Appendix S2 Derivation of the probability density function for
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